Inflation Remains Sticky in February: 5 Safe Picks
https://www.zacks.com/stock/news/2240004/inflation-remains-sticky-in-february-5-safe-picks?cid=CS-ZC-FT-analyst_blog|investment_ideas-2240004
Mar 13, 2024 - We have narrowed our search to five low-beta stocks with a solid dividend yield. These are: TAP, TSN, TM, GSK and BAH.
0
Has GSK PLC Sponsored ADR (GSK) Outpaced Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2239919/has-gsk-plc-sponsored-adr-gsk-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2239919
Mar 13, 2024 - Here is how GSK (GSK) and Capricor Therapeutics (CAPR) have performed compared to their sector so far this year.
0
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
https://www.zacks.com/stock/news/2240223/regulus-rgls-up-71-on-topline-data-from-kidney-disease-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240223
Mar 13, 2024 - Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
0
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab
https://www.zacks.com/stock/news/2240861/pfizer-pfe-gets-eu-nod-for-expanded-use-of-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240861
Mar 14, 2024 - Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
0
GSK (GSK) Increases Yet Falls Behind Market: What Investors Need to Know
https://www.zacks.com/stock/news/2243108/gsk-gsk-increases-yet-falls-behind-market-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2243108
Mar 19, 2024 - In the most recent trading session, GSK (GSK) closed at $42.32, indicating a +0.43% shift from the previous trading day.
0
GSK (GSK) Stock Moves -0.09%: What You Should Know
https://www.zacks.com/stock/news/2246352/gsk-gsk-stock-moves-0-09-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2246352
Mar 26, 2024 - GSK (GSK) closed at $42.79 in the latest trading session, marking a -0.09% move from the prior day.
0
GSK (GSK) Registers a Bigger Fall Than the Market: Important Facts to Note
https://www.zacks.com/stock/news/2249459/gsk-gsk-registers-a-bigger-fall-than-the-market-important-facts-to-note?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2249459
Apr 02, 2024 - GSK (GSK) concluded the recent trading session at $41.79, signifying a -1.49% move from its prior day's close.
0
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2250492/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2250492
Apr 04, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
GSK (GSK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
https://www.zacks.com/stock/news/2251483/gsk-gsk-rises-yet-lags-behind-market-some-facts-worth-knowing?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2251483
Apr 05, 2024 - GSK (GSK) concluded the recent trading session at $41.19, signifying a +0.81% move from its prior day's close.
0
GSK, Pfizer-backed ViiV gets FDA okay for HIV drug for adolescents
https://seekingalpha.com/news/4087977-gsk-pfizer-backed-viiv-gets-fda-okay-for-hiv-drug-for-adolescents?source=feed_sector_healthcare
Apr 08, 2024 - ViiV Healthcare said it has received FDA approval for its drug Dovato in the treatment of HIV-1 infection in adolescents 12 years old and older. Read more here.
0